Food and Drug Administration (FDA) has approved semaglutide (marketed as Wegovy) and Tirzepatide (marketed as Zepbound) specifically for chronic weight management in adults with obesity or overweight individuals with at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol
These second order effects will become more far reaching as insurance coverage becomes wider for these drugs - this will be the differentiator between the risk/reward being better on the first-order beneficiaries (LLY and NVO) and the second-order plays like short bariatric surgery/sleep apnea/gyms/fast food & CPG
Im not on any Berberine meds, but Ive been using the patch on its own for about 5 weeks
Final Thoughts GLP-1 medications have transformed how we treat obesity: Semaglutide broke ground with ~15% average weight loss
The post says current evidence suggests GLP-1 medications do not directly worsen IBD inflammation, and that early observational data and clinical experience do not show them typically triggering or exacerbating ulcerative colitis flares
The benefits often appear before weight loss occurs - cardiovascular risk drops within weeks, kidney function stabilizes, inflammation decreases, insulin sensitivity improves, and even osteoarthritis pain reduces as metabolic health improves